Semaglutide and Tirzepatide Together: What Is Known
Semaglutide and Tirzepatide taken together: what each one is, how each is regulated, and what is known about combining them.
Timing, interactions and safety
Evidence for the combination
- SURMOUNT-5: head-to-head randomized trial of tirzepatide versus semaglutide in adults with obesity. · PMID 40353578
- SURPASS-2: head-to-head randomized trial of tirzepatide versus semaglutide 1 mg in type 2 diabetes. · PMID 34170647
- Observational cohort study comparing weight loss on tirzepatide and semaglutide (not randomized). · PMID 38976257
- Real-world observational cohort comparing semaglutide with tirzepatide for cardiovascular outcomes (not randomized). · PMID 41491349
- Claims-data cohort study in HFpEF that includes a head-to-head tirzepatide versus semaglutide comparison (not randomized). · PMID 40886075
- Zepbound label, Indications and Usage (Limitations of Use; not Section 7): coadministration with any GLP-1 receptor agonist is not recommended. · FDA label
- Wegovy label, Indications and Usage (Limitations of Use; not Section 7): concomitant use with any other GLP-1 receptor agonist is not recommended. · FDA label
Side by side
Showing 7 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Semaglutide | Tirzepatide |
|---|---|---|
| Class | GLP-1 agonist | GLP-1 / GIP dual agonist |
| Also called | sema, Ozempic, Wegovy, Rybelsus, Wegovy pill | tirz, tirze, Mounjaro, Zepbound |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | FDA approved (Ozempic, Wegovy, Rybelsus) | FDA approved (Mounjaro, Zepbound) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | approximately 1 weeksubcutaneous · FDA label (Ozempic) | approximately 5 dayssubcutaneous · FDA label (Mounjaro) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 | Human RCT evidence, 4 of 4Strongest: Arthritis & rheumatology 2026, PMID 41903163 |
| Human studies we summarised | 23 human (19 randomized or controlled) of 27 summarised | 24 human (22 randomized or controlled) of 30 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 120 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Semaglutide vs Tirzepatide
Choosing between the two rather than combining them? The comparison lines them up field by field.
The comparisons all give people one drug, not both
In SURMOUNT-5, adults with obesity and no diabetes were randomised to one drug or the other, each at the maximum tolerated dose, so nobody received the two together.[12]
At week 72 the average weight change was larger on tirzepatide than on semaglutide in that trial.[12]
In SURPASS-2, which enrolled people with type 2 diabetes, HbA1c fell further at every tirzepatide dose than on semaglutide.[14]
A US real-world cohort comparing the two found similar rates of gastrointestinal adverse events between groups. It was observational, so patients were not randomly assigned.[15]
What each label says about using both
Zepbound's label says to avoid pairing it with any GLP-1 receptor agonist, which includes semaglutide.[18]
Wegovy's label says the same in reverse: it is not recommended with another semaglutide product or any other GLP-1 receptor agonist.[19]
Wegovy's label carries a boxed warning: in rodents, semaglutide causes thyroid C-cell tumours, and the human relevance has not been determined.[19]
Zepbound has a matching boxed warning: in rats, tirzepatide causes dose-dependent thyroid C-cell tumours at clinically relevant exposures.[18]
Compounded versions
FDA's page on unapproved GLP-1 drugs notes that compounded semaglutide and tirzepatide are not reviewed by the agency for safety, effectiveness or quality before marketing.[22]
FDA has received adverse event reports that may be related to compounded semaglutide or tirzepatide prescribed at doses above the approved label. Patients reported symptoms including nausea, vomiting, diarrhea, abdominal pain and constipation.[22]
Common questions
Is tirzepatide better than semaglutide?
In the one randomised obesity head-to-head, average weight loss at week 72 was greater with tirzepatide (-20.2%) than semaglutide (-13.7%); the trial was open-label.[12]
Can you take tirzepatide and semaglutide together?
No: the Zepbound label does not recommend combining it with any GLP-1 receptor agonist, and the Wegovy label says the same for other semaglutide products.[18]
Tirzepatide or semaglutide for type 2 diabetes?
SURPASS-2 concluded that, in patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide on HbA1c change at 40 weeks.[14]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 9These highlights do not include all the information needed to use MOUNJARO safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO ® (tirzepatide) Injection, for subcutaneous uFDA label (Mounjaro), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 10Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026PMID 41903163Accessed 2 Oct 2026
- 11Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.Obesity (Silver Spring, Md.) · 2026PMID 41537305Accessed 2 Oct 2026
- 12Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.The New England journal of medicine · 2025PMID 40353578Accessed 2 Oct 2026
- 13PubMed search: (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab]) AND (tirzepatide[tiab] OR Mounjaro[tiab] OR Zepbound[tiab] OR LY3298176[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.The New England journal of medicine · 2021PMID 34170647Accessed 2 Oct 2026
- 15Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.JAMA internal medicine · 2024PMID 38976257Accessed 2 Oct 2026
- 16Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).Diabetes, obesity & metabolism · 2026PMID 41491349Accessed 2 Oct 2026
- 17Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.JAMA · 2025PMID 40886075Accessed 2 Oct 2026
- 18ZEPBOUND prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 19WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 20Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
- 21Tirzepatide Once Weekly for the Treatment of Obesity.The New England journal of medicine · 2022PMID 35658024Accessed 2 Oct 2026
- 22Official web pageOfficial web page · web page
Found an error? Report a correction.